This is a minor operational update for a pre-revenue micro-cap. The enrollment completion is mildly positive but expected, and the stock has historically traded down on similar neutral/positive news. Key catalyst is the December 2026 CBR readout and the near-term interim report. Traders should not overweight this announcement given the company's cash constraints (likely need for financing before Phase 3) and the negative historical P&L on prior reports.
Price Chart
Executive Summary
AIM ImmunoTech announced ahead-of-schedule enrollment completion for its Phase 2 DURIPANC trial (Ampligen + Imfinzi in metastatic pancreatic cancer). Final subject enrollment closed before the original July 2026 target, with primary endpoint (Clinical Benefit Rate) evaluation planned for December 2026. This is a minor operational milestone for an early-stage, pre-revenue biotech with a $7M market cap and multiple prior neutral/bearish trading outcomes.
Key Facts
- Enrolled final subject in Phase 2 DURIPANC trial (Ampligen + Imfinzi for metastatic pancreatic cancer) ahead of the original July 2026 target.
- Final subject scheduled for treatment in mid-June 2026.
- Primary endpoint (Clinical Benefit Rate) evaluation planned for December 2026.
- Next interim report expected in 2–3 weeks.
- AIM has orphan drug designations in the US and Europe for Ampligen in pancreatic cancer.
- Company is a pre-revenue, early-stage biotech with a market cap of approximately $7M.
Financial Impact
No financial figures provided; pre-revenue company. Operational milestone only.
Risk Factors
- Pre-revenue company with ~$7M market cap — high cash-burn risk and likely need for dilutive financing before Phase 3 initiation.
- Pancreatic cancer trial is early stage (Phase 2, single-center, open-label); results may not replicate in larger, blinded Phase 3.
- Final CBR readout not due until December 2026 — no near-term catalyst beyond interim report.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304404 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 25d ago | DEF 14A | $0.1877 | awaiting T+20 | — | $0.1600 (−14.76%) |
Sep 22, 2026 4w ago | Press Release | $0.2156 $0.1662 | ▼ −22.91% | ▼ −22.35% | $0.1600 (−25.79%) |
Sep 14, 2026 5w ago | 8-K | $0.2100 | awaiting T+20 | — | $0.1600 (+23.81%) |
Aug 11, 2026 10w ago | 8-K | $0.2500 $0.2332 | ▼ −6.72% | ▼ −5.66% | $0.1600 (−36.00%) |
Aug 10, 2026 10w ago | 8-K | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 10, 2026 10w ago | Press Release | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 5, 2026 11w ago | 8-K | $0.2800 $0.2346 | ▼ −16.21% | ▼ −15.61% | $0.1600 (−42.86%) |
Aug 3, 2026 11w ago | Press Release | $0.2600 $0.2260 | ▼ −13.08% | ▼ −14.31% | $0.1600 (−38.46%) |
Jun 24, 2026 17w ago | EFFECT | $0.3740 $0.2534 | ▲ +32.25% | ▲ +34.18% | $0.1600 (+57.22%) |
Jun 18, 2026 18w ago | S-1 | $0.3799 $0.2730 | ▲ +28.14% | ▲ +28.67% | $0.1600 (+57.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers